和黄医药

最新新闻

• Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
  Gelonghui Finance · 2026/9/3
• Hutchmed (00013.HK): The SAFFRON global Phase III study of savolitinib has yielded positive results, potentially accelerating its global regulatory submissions.
  Dongwu Securities · 2026/8/18
• 评级变动
  Hutchmed (0013.HK): The innovative drug segment posted a steady recovery in 1H26, with a flurry of catalysts expected in 2H26–2027; target price raised.
  Bank of Communications International · 2026/8/3
• 评级变动
  CICC maintains an 'Outperform Industry' rating for Hutchmed (00013) with a target price of 30 Hong Kong dollars.
  Zhitong Finance · 2026/3/12
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 公司公告
  Paycor HCM: Paycor HCM, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: PYCR
  OCC · 2025/4/14
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6
  \u5e02\u573a\u8d44\u8baf · 2026/5/29
• Daiwa upgrades HUTCHMED (00013.HK) to “Buy,” raising target price to HK$28.5
  AASTOCKS · 2026/9/4
• 公司公告
  Paycor HCM (Delisted) | 4: Statement of changes in beneficial ownership of securities-Officer VILLAR RAUL JR.
  SEC · 2025/4/16
• 公司公告
  Paycor HCM: Paycor HCM, Inc. - Anticipated Cash Settlement Option Symbol: PYCR
  OCC · 2025/2/20
• 公司公告
  Paycor HCM | 4: Statement of changes in beneficial ownership of securities-Officer VILLAR RAUL JR.
  SEC · 2025/4/3
• 公司公告
  Paycor HCM | 4: Statement of changes in beneficial ownership of securities-Officer VILLAR RAUL JR.
  SEC · 2025/1/4
• 评级变动
  Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/3/10
• Hutchmed (China) Target Price Raised to HK$39.00 From HK$36.00 by Citi Research 0013.HK
  Dow Jones · 2026/9/4
• 评级变动
  BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/1/22
• Hutchmed (00013.HK) announced the submission of a New Drug Application (NDA) in the United States for the combination of ORPATHYS and TAGRISSO for the treatment of MET-driven EGFR-mutated lung cancer.
  Gelonghui Finance · 2026/9/29

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。